Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study

John B. Buse(University of North Carolina at Chapel Hill), Michael A. Nauck(Diabeteszentrum Bad Lauterberg), Thomas Först(Institut für Klinische Forschung und Entwicklung), Wayne H.-H. Sheu(National Yang Ming Chiao Tung University), Sylvia Shenouda(Eli Lilly (United States)), Cory R. Heilmann(Eli Lilly (United States)), Byron J. Hoogwerf(Eli Lilly (United States)), Aijun Gao(Cincinnati Health Department), Marilyn K Boardman(Eli Lilly (United States)), Mark Fineman, Lisa A. Porter, Guntram Schernthaner(Rudolfinerhaus Hospital)
The Lancet
November 6, 2012
Cited by 563

Abstract


Related Papers

No related papers found

Powered by citation graph analysis